Evidence map›Paper›PMID 25120707›Full record

ArticleOncology letters2014

Oral malignant melanoma: A report of two cases with BRAF molecular analysis.

Pier Francesco Soma, Angela Pettinato, Anna Maria Agnone, Claudio Donia, Giuseppina Improta, Filippo Fraggetta

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Oncology letters · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Pier Francesco SomaHealthcare Burns Unit, Cannizzaro Hospital, Catania 95126, Italy.
Angela PettinatoPathology Unit, Cannizzaro Hospital, Catania 95126, Italy.
Anna Maria AgnoneDental Institute, Cannizzaro Hospital, Catania 95126, Italy.
Claudio DoniaUnit of Plastic Surgery, Vittorio Emanuele II Hospital, Castelvetrano (TP) 91022, Italy.
Giuseppina ImprotaLaboratory of Clinical Research and Advanced Diagnostics, IRCCS-CROB, Rionero in Vulture (PZ) 85028, Italy.
Filippo FraggettaPathology Unit, Cannizzaro Hospital, Catania 95126, Italy.
Ospedale Cannizzaro · ITCentro di Riferimento Oncologico della Basilicata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary oral malignant melanoma is a rare condition, accounting for 1.3-1.4% of all melanomas, usually presenting with an aggressive clinical behavior. The present study reports the clinicopathological findings of two cases of oral malignant melanoma and discusses the epidemiology, diagnosis and current therapeutic approaches for this uncommon condition. In the first case the patient presented with a pigmented lesion located on the lower mucosal lip. The patient showed no nodal metastases and therefore, underwent a wedge resection. After seven months, the patient presented with neck lymph nodes and multiple visceral metastases. Molecular analysis of BRAF, using a pyrosequencing approach, revealed the presence of BRAF V600E mutation. The patient developed multiple visceral metastases, but refused treatment and was lost to follow-up. In the second case, no BRAF V600E mutation was found, but the patient exhibited a pigmented patch in the lower gingival mucosa, which was excised by surgical treatment. The patient was followed up by an oncologist, but did not undergo an additional therapy and is currently alive with no evidence of visceral metastases at one year following the diagnosis.

Indexed as

BRAF mutationsoral malignant melanomatherapeutic approaches

Identifiers

PMID25120707
PMCPMC4114621
OpenAlexW2020115294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.